Valerie, a wellness brand focused on perimenopause support, has secured £514,000 in pre-seed funding to expand its product line featuring patent-pending liposomal technology, the company announced today.
The funding round was led by notable angel investors, including Giles Brook, former CEO of Vita Coco and investor in brands such as Surreal, Pip & Nut, and Freja. According to the company, 45% of the investment came from women, significantly higher than the industry average where just 14% of total angel investors are female.
“We’re rethinking a category with unflinchingly real, big, bold energy and moments of mischief to build engaged community, coupled with a liquid supplement, Daily Essential, using patent-pending liposomal technology that’s genuinely changing women’s lives,” said Valerie Co-founder Olly Johnson in a statement on LinkedIn.
Valerie’s flagship product, Daily Essential, uses liposomal technology to deliver nutrients targeted at perimenopause symptoms. The company reports strong early growth metrics, with Q1 2025 sales increasing 84% compared to Q4 2024, and projections to reach seven-figure revenue this year.
The brand has positioned itself in the rapidly growing perimenopause wellness market, noting that perimenopause-related search terms are growing four times faster than menopause searches.
The funding will support Valerie’s continued growth and product development in the women’s health sector.
